Ubiquitin and proteasome pathways
Ubiquitin and proteasome pathways is a research topic within Molecular Biology. Science Explorer counts 44k research works in it since 1950. 24.3% of them reached the world's top 10% most cited for their field and year.
This cluster of papers focuses on the Ubiquitin-Proteasome Proteolytic Pathway, exploring mechanisms of protein degradation, regulation of E3 Ubiquitin Ligases, roles of Deubiquitinating Enzymes, and the impact of SUMOylation. It also delves into the development of proteasome inhibitors for cancer therapy and the involvement of this pathway in NF-?B activation.
- Ubiquitin
- Proteasome
- Deubiquitinating Enzymes
- E3 Ubiquitin Ligases
- SUMOylation
- Protein Degradation
- Polyubiquitin Chains
- Proteasome Inhibitors
- NF-?B Activation
- Cancer Therapy
- Research works
- 44k fractional, since 1950
- In the world top 10%
- 11k per year above
- Top-10% rate
- 24.3% share of its works in the world top 10%
- Growth, 2013–17 → 2018–22
- +3% the tick is no change
Which countries lead Ubiquitin and proteasome pathways research?
By volume, China and the United States publish the most (2.8k and 1.8k works in 2022–2025).
By volume, 2022–2025
- 1 China 2.8k works
- 2 United States 1.8k works
- 3 Germany 305 works
- 4 Japan 270 works
- 5 United Kingdom 260 works
- 6 India 242 works
- 7 South Korea 178 works
- 8 Canada 165 works
- 9 Italy 162 works
- 10 France 160 works
How concentrated that is
The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.
Shares of the rows listed above, not of the whole node.
Which institutions lead Ubiquitin and proteasome pathways research?
By volume in 2022–2025, Chinese Academy of Medical Sciences & Peking Union Medical College publishes the most Ubiquitin and proteasome pathways research, followed by Sun Yat-sen University and Zhejiang University.
By volume, 2022–2025
- 1 Chinese Academy of Medical Sciences & Peking Union Medical College China 40 works
- 2 Sun Yat-sen University China 40 works
- 3 Zhejiang University China 39 works
- 4 Harvard University United States 39 works
- 5 Shanghai Jiao Tong University China 36 works
- 6 University of North Carolina at Chapel Hill United States 35 works
- 7 Central South University China 33 works
- 8 Chinese Academy of Sciences China 33 works
- 9 China Pharmaceutical University China 32 works
- 10 The University of Texas MD Anderson Cancer Center United States 31 works
Who are the leading researchers in Ubiquitin and proteasome pathways?
The most-cited researchers publishing on Ubiquitin and proteasome pathways include Robert A. Weinberg, Matthias Mann and Gordon B. Mills.
- 1 Robert A. Weinberg 8.3k citations
- 2 Matthias Mann 5.1k citations
- 3 Gordon B. Mills 3.7k citations
- 4 E. J. Corey 3.6k citations
Ranked by citations received across their whole record, among researchers with at least three works on this topic.
Where is Ubiquitin and proteasome pathways research done?
The largest centres of Ubiquitin and proteasome pathways research in 2022–2025 are Beijing (China), Shanghai (China), Guangzhou (China) and Hangzhou (China). Among places with at least 20 works in it, it is an unusually large share of all research in Dundee and Nantong.
Largest cities, 2022–2025
Where it is the local speciality
- DundeeGB · 26.7 works16×
- NantongCN · 26.0 works7.8×
Location quotient: how much more of its research is in Ubiquitin and proteasome pathways than the world average.
Where is the best place to study Ubiquitin and proteasome pathways?
Among universities, judged by research, China Pharmaceutical University, Center for Life Sciences and University of Dundee score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.
One dot per university in the table below. The upper left is the interesting corner: small places doing unusually strong work.
| # | University | Score | Top 10% | Specialisation | Works | Growth |
|---|---|---|---|---|---|---|
| 1 | China Pharmaceutical University China | 74.3 | 41.0% | 20.9× | 32 | +102.0% |
| 2 | Center for Life Sciences China | 68.8 | 42.4% | 21.6× | 8 | +395.6% |
| 3 | University of Dundee United Kingdom | 64.0 | 35.8% | 19.0× | 20 | +18.8% |
| 4 | Nanjing Medical University China | 61.5 | 32.0% | 8.0× | 29 | +93.7% |
| 5 | China Medical University China | 58.5 | 30.2% | 12.4× | 28 | -16.7% |
| 6 | Second Military Medical University China | 56.4 | 35.7% | 14.4× | 12 | +62.5% |
| 7 | Sun Yat-sen University China | 55.2 | 34.8% | 3.5× | 40 | +86.1% |
| 8 | Harvard University United States | 54.3 | 35.0% | 4.3× | 39 | -20.4% |
| 9 | Shanghai University of Traditional Chinese Medicine China | 53.9 | 31.4% | 7.7× | 11 | +199.3% |
| 10 | Nanjing University of Chinese Medicine China | 53.1 | 35.4% | 8.3× | 15 | — |
Universities only. Score blends excellence (30%), specialisation (25%), size (20%), growth (15%) and international reach (10%), 2015–2022; growth compares 2010–14 with 2015–19.
Is Ubiquitin and proteasome pathways research growing?
Output in 2018–2022 was 3% higher than in 2013–2017, peaking in 2025. The fastest-growing topics are Ubiquitin and proteasome pathways.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Which topics inside it are moving
Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.